Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis by Chang Seok Bang et al.
RESEARCH ARTICLE Open Access
Portal hypertensive gastropathy as a
prognostic index in patients with liver
cirrhosis
Chang Seok Bang1†, Hyo Sun Kim1†, Ki Tae Suk1, Sung Eun Kim1, Ji Won Park1, Seung Ha Park2, Hyoung Su Kim1,
Myoung Kuk Jang1, Sang Hoon Park1, Myung Seok Lee1, Choong Kee Park1 and Dong Joon Kim1*
Abstract
Background: Portal hypertensive gastropathy (PHG) is a frequently overlooked complication of liver cirrhosis (LC).
The clinical implications of PHG as a prognostic factor of LC or a predictive factor for the development of
hepatocellular carcinoma (HCC) have not been established. The aim of this study was to assess the clinical
significance of PHG in patients with LC.
Methods: Patients with LC were prospectively enrolled and followed in a single tertiary hospital in the Republic of
Korea. Baseline hepatic vein pressure gradient (HVPG) was measured, and esophagogastroduodenoscopy (EGD) was
performed. The associations of PHG with HVPG, survival and the development of HCC were evaluated.
Results: A total of 587 patients were enrolled. The mortality rate was 20.3 % (n = 119), and HCC developed in 9.2 %
(n = 54) during the follow-up period (32.6 ± 27.8 months). The grade of PHG was well correlated with HVPG (no
PGH: median 9.2 [IQR: 7.2–16.7], mild PHG: 14.6 [10.1–19.3], and severe PHG: 17.3 [12.3–21.5], P < 0.001), as well as
with Child-Pugh class, MELD score or survival. However, it was not associated with the development of HCC. The
grade of PHG (HR 3.29, 95 % CI: 1.12–9.63, severe vs. no PHG) and Child-Pugh class (HR 3.53, 95 % CI: 1.79–6.97,
Child C vs A) showed significant associations with mortality.
Conclusion: PHG was well correlated with portal hypertension and could be used as a prognostic factor for LC but
not for the prediction of HCC.
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Background
Portal hypertension is a complication of liver cirrhosis (LC) and
the main pathophysiologic mechanism that potentiates various
adverse gastrointestinal consequences, including esopha-
geal or gastric varices, gastropathy, and enteropathy [1, 2].
Portal hypertensive gastropathy (PHG) is a frequently
overlooked complication in patients with LC. More atten-
tion has been focused on the detection or evaluation of
esophageal or gastric varices by endoscopists. This com-
plex secondary change in the gastric mucosa resulting
from portal hypertension is a potential cause of acute or
chronic hemorrhage [3]. It can also be severe and fatal, al-
though less frequently than variceal hemorrhage [4].
In addition to the potential hemorrhagic focus, the clin-
ical implications of PHG have not been well established.
Previous studies have also shown conflicting results re-
garding the correlation between PHG and the severity of
liver disease [5–13]. The aim of this study was to evaluate
the clinical implications of PHG as a prognostic factor of
LC or a predictive factor for the development of hepato-
cellular carcinoma (HCC) in patients with LC.
Methods
Patients
Patients with chronic liver disease were prospectively
enrolled and followed in a single tertiary hospital in the
Republic of Korea. Baseline hepatic vein pressure gradient
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(HVPG) was measured, and esophagogastroduodenoscopy
(EGD) was performed in all consecutive patients for the
detection or evaluation of the severity of PHG. Both pro-
cedures were performed consecutively and the time inter-
val between 2 procedures was minimal. Patients without
LC or with incomplete data were excluded from this
study. The clinical and endoscopic characteristics of
patients with LC were reviewed and analyzed. Data were
recorded for the following variables: sex, age, the etiology
of LC, endoscopic findings, laboratory findings, and
HVPG. Laboratory findings including Child-Pugh classifi-
cation and Model for End-stage Liver disease (MELD)
score were assessed based on hospitalization day.
Differentiation of etiology
The differentiation between LC and chronic hepatitis
relied on clinical, laboratory, radiologic and histologic
information. The final determination of LC was made by
two hepatologists (K.T.S and D.J.K).
In terms of the etiology, chronic hepatitis B was de-
fined as positive for hepatitis B surface antigen (HBsAg)
with abnormal levels of aspartate transaminase (AST) /
alanine transaminase (ALT) for a period longer than
6 months. Chronic hepatitis C was defined as positivity
for hepatitis C antibodies (Anti-HCV) and serum RNA
(HCV-RNA) with abnormal levels of AST/ALT for a
period longer than 6 months. Determination of alcoholic
hepatitis used history of alcohol abuse (>40 g/day for
men, >20 g/day for women) [14, 15], physical findings
(delirium tremens or alcohol withdrawal seizure), labora-
tory tests (AST/ALT >2, elevated level of gamma glutamyl
transpeptidase, or enlarged mean corpuscular volume), or
liver biopsy (steatosis, hepatocyte ballooning, Mallory-Denk
bodies, megamitochondria, canalicular and/or lobular
bilirubinostasis, or polymorphonuclear neutrophil in-
filtration), after excluding other potential etiologies.
The determination of non-alcoholic steatohepatitis
relied on history (exclusion of significant alcohol con-
sumption), laboratory tests (AST or ALT elevation),
imaging modalities (hepatic steatosis), or liver biopsy
(macrovesicular fatty changes, hepatocyte ballooning, or
inflammatory cell infiltrate), after excluding other poten-
tial etiologies.
Endoscopy and HVPG measurement
PHG was evaluated by EGD performed by 6 experienced
endoscopists (>6000 cases of endoscopy). The diagnosis
and determination of degree were based on the Baveno
III scoring system [16]. To minimize the inter-observer
variability, all of the endoscopic data and diagnoses were
reviewed by 6 experienced endoscopists. Cases of dis-
agreement were discussed and resolved by consensus,
according to the Baveno III scoring system. To exclude
single gastric antral vascular ectasia cases, not relevant
to portal hypertension, authors categorized enrolled
population according to the presence of PHG or not
(binary criteria), in addition to the Baveno III scoring
system for PHG, and six experienced endoscopists made
decisions by consensus.
HVPG was measured with transjugular access under
fluoroscopic guidance by 2 experienced hepatologists
(K.T.S and S.H.P >300 cases of HVPG measurements).
A catheter was placed into one of the hepatic vein
branches, and the pressure was measured three times
using the ballooning and deballooning method of the
hepatic vein. The average number was recorded and de-
cided upon as the patient’s HVPG. Informed consent
was obtained. Vital signs were continuously monitored,
Fig. 1 Flow diagram of study design
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and the patients were observed carefully to detect the
development of serious complications during and after
the measurement of HVPG.
Statistical analysis
Continuous variables are expressed as the medians and
interquartile ranges (IQRs) because they were not nor-
mally distributed. Categorical variables are expressed as
numbers and percentages. The Mann-Whitney test and
Fisher’s exact test were used to compare two variables.
The Kruskal-Wallis test and Fisher’s exact test were used
to evaluate the three study arms. Post hoc analysis was
performed using Bonferroni’s correction. Survival ana-
lysis, including the development of HCC, was performed
using the Kaplan-Meier method and the log rank test.
The Cox proportional hazard model was applied for the
detection of associated factors for survival and the devel-
opment of HCC. A P value < 0.05 (2-tailed) was adopted
as the threshold of statistical significance for all of the
tests. The analysis was performed using SPSS software,
version 21.0 (SPSS Inc., Chicago, IL, USA). All of the
authors had access to the study data and reviewed and
approved the final manuscript.
Results
Characteristic of patients
Between January 2006 and May 2013, 1002 patients were
initially enrolled. Patients without LC or with incomplete
data were excluded from this study. The number of ex-
cluded cases from each category was as follows: no LC
(n = 373), incomplete endoscopic evaluation (n = 37),
and incomplete HVPG measurement (n = 5). Finally, 587
patients were included in the analysis of this study
(Fig. 1).
The clinical characteristics of these patients are sum-
marized in Table 1. The median age was 51 years old
(IQR: 45–59) in the total population. Male predomin-
ance was observed in the collected data for 78.7 % of the
total patients. In terms of the etiology, alcohol abuse was
the most frequent cause of LC (69.8 %), followed by
hepatitis B virus (HBV) infection (24.2 %), hepatitis C
virus (HCV) infection (5.8 %), and non-alcoholic causes
(0.2 %).
Regarding the severity of LC, approximately half of the
patients were included in Child-Pugh classification A
(48.2 %), followed in order by B (39.9 %) and C (11.9 %).
The median value of HVPG was 14.8 (IQR: 10–20), and
the MELD score was 9.3 (IQR: 5.7–13.0).
PHG was detected in 91.5 % of the patients. Among
the patients with PHG, the severe category constituted
21.5 %, and 70 % of the patients showed mild PHG.
Patients with only gastric antral vascular ectasia was 3
(0.51 %). During the follow-up period (32.59 ±
27.77 months), the overall survival rate was 79.7 %, and
9.2 % of the patients developed HCC. The proportion
patients lost to follow-up was 12.8 % (n = 75).
There were no serious complications during or after
HVPG measurements. Transient ventricular premature
contraction was frequently noted when the tip of the
measurement catheter passed the right atrium. Cardiac
rhythm recovered without any treatment after a few
seconds.
Univariate analysis for PHG
The univariate analyses for PHG in LC are listed in
Tables 2 and 3. There were significant differences in the
distributions of Child-Pugh classification, HVPG, and
MELD score, as well as laboratory parameters, between
patients with and without PHG (Table 2). In the analysis
stratified by the severity of PHG (no PHG vs mild PHG
vs severe PHG), this finding was consistent (Table 3).
Table 1 Clinical characteristics of total patients
Characteristics, N (%) Total (N = 587)
Age (years), Median (Interquartile range) 51 (45–59)
Sex
Male 462 (78.7 %)
Female 125 (21.3 %)
Etiology
Alcohol 410 (69.8 %)
HBV 142 (24.2 %)
HCV 34 (5.8 %)
Non-alcoholic 1 (0.2 %)
PHG
No PHG 50 (8.5 %)
Mild PHG 411 (70 %)
Severe PHG 126 (21.5 %)
Child-Pugh classification
Class A 283 (48.2 %)
Class B 234 (39.9 %)
Class C 70 (11.9 %)
HVPG (mmHg), Median (Interquartile range) 14.8 (10–20)
MELD score 9.3 (6.0–13.0)
Albumin (g/dL) 3.3 (2.8–3.8)
Total bilirubin (mg/dL) 1.4 (0.8–2.7)
Platelet count (x 103/mL) 105 (74–160)
Prothrombin time (INR) 1.26 (1.11–1.44)
Follow-up duration (months), Mean ± SD 32.59 ± 27.77
Survival 468 (79.7 %)
HCC 54 (9.2 %)
N number, HBV hepatitis B virus, HCV hepatitis C virus, PHG portal hypertensive
gastropathy, HVPG hepatic vein pressure gradient, MELD model for end-stage
liver disease, INR international normalized ratio, SD standard deviation, HCC
hepatocellular carcinoma
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In the analysis of survival, patients without PHG
showed a higher survival rate than patients with PHG
(92 % vs 78.6 %, 95.33 ± 3.78 vs 74.53 ± 2.21 months, P =
0.004) (Table 2 and Fig. 2a). This finding was also con-
sistent with the analysis stratified by the severity of PHG
(severe PHG vs mild PHG, P = 0.008; severe PHG vs no
PHG, P < 0.001; mild PHG vs no PHG, P = 0.008)
(Table 3, Fig. 2b). The detailed survival months and sur-
vival rates are reported in Table 4.
For the development of HCC, there was no significant
difference between patients with or without PHG (9.1 %
vs 10 %, P = 0.33) (Table 2). This finding was also consist-
ent with the analysis stratified by the severity of PHG (se-
vere PHG vs mild PHG: P = 0.63; severe PHG vs no PHG:
P = 0.34; mild PHG vs no PHG: P = 0.32) (Table 3).
The distribution of sex and etiology of LC was differ-
ent between patients with PHG and without PHG. How-
ever, the survival rate was not different between men
and women (P = 0.44, log-rank test). In terms of the eti-
ology of LC, the survival rate was only different between
patients with CHB-associated LC and those with alco-
holic LC (P = 0.03) (Fig. 3). The development of HCC
was not significantly different between men and women
(P = 0.66, log-rank test). In terms of the etiology of LC,
the survival rate was not also different according to the
etiology (Additional file 1: Figure S1).
Multivariate analysis for the prediction of survival in
patients with LC
In the multivariate analysis of independent risk factors
for survival, PHG (severe PHG vs no PHG, HR: 3.29,
95 % CI: 1.12–9.63, P = 0.03) and Child-Pugh classifica-
tion (Child C vs A, HR: 3.53, 95 % CI: 1.79–6.97, P <
0.001) (Child B vs A, HR: 2.15, 95 % CI: 1.35–3.44, P =
0.001) showed statistically significant associations with
survival in patients with LC. Age (HR 1.03, 95 % CI:
1.01–1.06, P = 0.001) and HVPG (HR 1.06, 95 % CI:
1.03–1.08, P < 0.001) showed marginal statistical signifi-
cance (Table 5). This analysis was controlled for age, sex,
etiology of LC, and MELD score.
Discussion
Blood flow congestion secondary to portal hypertension
is considered the primary cause of PHG [17]. Imbalances
between mucosal protective mechanisms and injury fac-
tors resulting from mucosal hemodynamic alterations
are believed to induce PHG [18]. Although portal hyper-
tension is the prerequisite for the development of PHG,
Table 2 Univariable analysis for PHG in patients with liver cirrhosis
Variables, N (%) No PHG PHG P value
N = 50 (8.5 %) N = 537 (91.5 %)
Age (years), Median (Interquartile range) 52 (43–60.25) 51 (45–59) 0.64
Sex 0.002
Male 30 (60 %) 432 (80.4 %)
Female 20 (40 %) 105 (19.6 %)
Etiology <0.001
Alcohol 20 (40 %) 390 (72.6 %)
HBV 26 (52 %) 116 (21.6 %)
HCV 4 (8 %) 30 (5.6 %)
Non-alcoholic 0 (0 %) 1 (0.2 %)
Child-Pugh classification <0.001
Class A 37 (74 %) 246 (45.8 %)
Class B 12 (24 %) 222 (41.3 %)
Class C 1 (2 %) 69 (12.8 %)
HVPG (mmHg), Median (Interquartile range) 9.2 (7.23–16.73) 15 (11–20) <0.001
MELD score 6.00 (6.00–8.07) 9.83 (6.00–13.58) <0.001
Albumin (g/dL) 3.7 (3.0–4.1) 3.2 (2.8–3.7) 0.001
Total bilirubin (mg/dL) 0.9 (0.6–1.2) 1.5 (0.9–2.9) <0.001
Platelet count (x 103/mL) 141.5 (94.8–214.3) 104 (71–157) 0.001
Prothrombin time (INR) 1.12 (1.04–1.32) 1.28 (1.12–1.45) <0.001
Survival 46 (92 %) 422 (78.6 %) 0.004
HCC 5 (10 %) 49 (9.1 %) 0.33
N number, HBV hepatitis B virus, HCV hepatitis C virus, PHG portal hypertensive gastropathy, HVPG hepatic vein pressure gradient, MELD model for end-stage liver
disease, INR international normalized ratio, SD standard deviation, HCC hepatocellular carcinoma
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various other factors, such as inflammatory response,
local vascular tone, hepatic function, gastric mucosal
perfusion, endotoxin, and gastric sucrose permeability,
are suspected to influence the development of PHG
[19–22]. Reversible mucosal changes in the stomach
have suggested that PHG is a dynamic condition [23, 24].
Several studies have evaluated the correlation of PHG with
the severity of liver disease or portal hypertension [5–13].
However, most of these studies have included small popu-
lations, and the association remains unclear. Our study in-
cluded the largest population (n = 587) and evaluated the
association of PHG with the development of HCC, as well
as with portal hypertension and survival.
PHG was detected in 91.5 % of the total population in
our study. This result was consistent with several previous
studies (90.1 % in the study by Kim et al. and 93.4 % in
the study by Curvêlo et al.) [7, 8]. The reported prevalence
of PHG has shown great variation (7–98 %) [25, 26].
Selection bias in the studies, inconsistent endoscopic diag-
nosis criteria, and the lack of interobserver reliability are
suspected causes of variation [27]. A recent study of the
reliability of endoscopic diagnosis in PHG showed unsatis-
factory results regarding the currently available diagnostic
criteria (Baveno, McCormack, and NIEC classification)
[27]. Binary criteria, such as the presence or absence of a
mosaic-like pattern, red-point lesions and cherry-red
spots, showed high inter-observer agreement and high
specificity [27]. To minimize bias, our study adopted an
analysis of group created according to the presence of
PHG or not (binary criteria), in addition to the Baveno III
scoring system for PHG, and six experienced endoscopists
made decisions by consensus.
In the analysis of the correlation between PHG and
the severity of liver disease, PHG showed correlations with
Child-Pugh classification, HVPG, and MELD score, as
well as laboratory parameters (Table 2). These correlations
Table 3 Univariable analysis for PHG in patients with liver cirrhosis
Variables, N (%) No PHG Mild PHG Severe PHG P value
N = 50 (8.5 %) N = 411 (70 %) N = 126 (21.5 %)
Age (years), Median (Interquartile range) 52 (43–60.25) 52 (46–60) 51 (45–56) 0.24
Sex 0.001
Male 30 (60 %) 324 (78.8 %) 108 (85.7 %)
Female 20 (40 %) 87 (21.2 %) 18 (14.3 %)
Etiology <0.001
Alcohol 20 (40 %) 284 (69.1 %) 106 (84.1 %)
HBV 26 (52 %) 99 (24.1 %) 17 (13.5 %)
HCV 4 (8 %) 27 (6.6 %) 3 (2.4 %)
Non-alcoholic 0 (0 %) 1 (0.2 %) 1 (0 %)
Child-Pugh classification <0.001
Class A 37 (74 %) 197 (47.9 %) 49 (38.9 %)
Class B 12 (24 %) 169 (41.1 %) 53 (42.1 %)
Class C 1 (2 %) 45 (10.9 %) 24 (19 %)
HVPG (mmHg), Median (Interquartile range) 9.2 (7.2–16.7) 14.6 (10.1–19.3) 17.3 (12.3–21.5) <0.001
MELD score 6.00 (6.00–8.07) 9.41 (6.00–12.85) 10.64 (6.94–14.73) <0.001
Albumin (g/dL) 3.7 (3.0–4.1) 3.3 (2.8–3.8) 3.2 (2.8–3.6) 0.001
Total bilirubin (mg/dL) 0.9 (0.6–1.2) 1.4 (0.8–2.5) 1.9 (1.0–4.3) <0.001
Platelet count (x 103/mL) 141.5 (94.8–214.3) 103 (75–156) 104 (66.8–167) 0.004
Prothrombin time (INR) 1.12 (1.04–1.32) 1.26 (1.11–1.44) 1.29 (1.15–1.49) <0.001
Survival 46 (92 %) 327 (79.6 %) 95 (75.4 %)
HCC 5 (10 %) 43 (10.5 %) 6 (4.8 %)
HVPG, Severe PHG vs Mild PHG: P = 0.001, Severe PHG vs No PHG: P < 0.001, Mild PHG vs No PHG: P < 0.001
MELD score, Severe PHG vs Mild PHG: P = 0.015, Severe PHG vs No PHG: P < 0.001, Mild PHG vs No PHG: P < 0.001
Albumin, Severe PHG vs Mild PHG: P = 0.18, Severe PHG vs No PHG: P < 0.001, Mild PHG vs No PHG: P = 0.002
Total bilirubin, Severe PHG vs Mild PHG: P < 0.001, Severe PHG vs No PHG: P < 0.001, Mild PHG vs No PHG: P < 0.001
Platelet, Severe PHG vs Mild PHG: P = 0.49, Severe PHG vs No PHG: P = 0.004, Mild PHG vs No PHG: P = 0.001
INR, Severe PHG vs Mild PHG: P = 0.14, Severe PHG vs No PHG: P < 0.001, Mild PHG vs No PHG: P < 0.001
Survival, Severe PHG vs Mild PHG: P = 0.08, Severe PHG vs No PHG: P < 0.001, Mild PHG vs No PHG: P = 0.008
HCC, severe PHG vs Mild PHG: P = 0.63, Severe PHG vs No PHG: P = 0.34, Mild PHG vs No PHG: P = 0.32
N number, HBV hepatitis B virus, HCV hepatitis C virus, PHG portal hypertensive gastropathy, HVPG hepatic vein pressure gradient, MELD model for end-stage liver
disease, INR international normalized ratio, SD standard deviation, HCC hepatocellular carcinoma
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Fig. 2 Survival curve according to the presence of PHG (a) and PHG grade (b). PHG, portal hypertensive gastropathy
Table 4 Survival rate according to the PHG grade
PHG grade Mean survival
(months), Mean ± SD
Survival rate Overall
mortality (%)1 year (%) 3 years (%) 7 years (%)
No PHG 95.33 ± 3.78 100 88.6 88.6 8
Overall PHG 74.53 ± 2.21 89.9 75.5 54.9 21.4
Mild PHG 76.68 ± 2.40 92.8 78.5 56.4 20.4
Severe PHG 55.48 ± 2.05 79.7 64.3 53.8 (5 years) 24.6
N number, PHG portal hypertensive gastropathy, SD standard deviation
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were also consistent in the analysis according to the sever-
ity of PHG (no PHG vs mild PHG vs severe PHG)
(Table 3). This finding was consistent with a recent
Korean study, which prospectively enrolled 331 patients
with LC [8]. Previous studies indicating no definite correl-
ation of PHG with the severity of liver disease have
suggested that various factors are associated with the
development of PHG [11, 12]. However, reversal or im-
provement of PHG was observed after treatment with
transjugular intrahepatic portosystemic shunt (TIPS), indi-
cating that portal hypertension is the main pathophysio-
logic mechanism of PHG [24]. These studies cannot
definitely explain the cause of reversal of PHG after TIPS.
Moreover, only small populations were included in these
studies. Large scale studies, including our study, have
shown a common association of PHG with the severity of
liver disease [8].
Prognostic implications of PHG were also assessed in
our study. The survival rates were statistically lower in
patients with PHG, and this finding was consistent in
the stratified analysis based on the severity of PHG
(Tables 2 and 3; Fig. 2). Another large-scale study by
Kim et al [8]. also showed consistent results. There
was a report indicating an association of HVPG with
mortality in patients with decompensated LC [28]. In
this study, the cut-off value of HVPG of 18 mm Hg
was associated with 2-year mortality in patients with
decompensated LC [28]. This value was similar to our
data of HVPG in patients with severe PHG (median
HVPG 17.3 of mm Hg). Without definite mucosal
hemorrhage, incidentally detected PHG is easily
neglected by endoscopists. Although this study cannot
provide histologic data about the liver, patients with
PHG should be considered to have more advanced
hepatic disease, associated with a poorer prognosis.
The presence of advanced hepatic fibrosis is related to
portal hypertension and the development of HCC. Thus,
early detection and treatment of liver fibrosis and its
complications are important. After the suggestion of
pathophysiologic classification of LC using HVPG by
Garcia-Tsao et al. [29], the association of HVPG and the
development of HCC have been studied. In a study of
patients with decompensated alcoholic LC, the cut-off
value for HVPG of 15 mm Hg was associated with the
development of HCC [30]. However, in another study of
patients with compensated LC, the cut-off value of
HVPG 10 mm Hg was associated with the development
of HCC [31]. According to our data, the presence of
PHG could be used as an index of prognosis. However,
the presence of PHG or the degree of PHG was not associ-
ated with the development of HCC. As shown in previous
studies, many factors are associated with the development
of HCC [32]. These factors include viral predisposing con-
ditions, environmental factors, age, sex, genetic susceptibil-
ity, and metabolic factors [32]. Considering the risk
persisting after sustained virological response in patients
with HCV-associated LC or even after HBsAg seroclear-
ance in patients with HBV infection, hemodynamic staging
alone cannot predict the development of HCC [33–35].
There were several limitations of our study. This study
lacked information about changes in PHG or HVPG ac-
cording to the treatment of LC. The association of the
development of PHG with esophageal or gastric varices
could not be assessed because various treatments or
even non-treated cases of varices were included in the
total population. Despite these limitations, our study in-
cluded the largest population, and long-term observation
Table 5 Multivariable analysis for the prediction of survival in patients with LC
Variables, n (%) HR (95 % CI) P value
PHG 3.29 (1.12–9.63) (Severe PHG vs No PHG) P = 0.03
Age 1.03 (1.01–1.06) P = 0.001
Child-Pugh classification 3.53 (1.79–6.97) (Child C vs A) P < 0.001
2.15 (1.35–3.44) (Child B vs A) P = 0.001
HVPG 1.06 (1.03–1.08) P < 0.001
Controlled for age, sex, etiology, and MELD score
N number, HVPG hepatic vein pressure gradient, PUD peptic ulcer disease, NSAIDs non-steroid anti-inflammatory drugs, LC liver cirrhosis, OR Odds ratio
Fig. 3 Survival curve according to the etiology of LC. LC, liver
cirrhosis; HBV, hepatitis B virus; HCV, hepatitis C virus
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was undertaken for the evaluation of prognosis and the
development of HCC.
Conclusion
In conclusion, PHG was well correlated with portal
hypertension. It could be used as a prognostic factor for
LC but not for the prediction of HCC.
Additional files
Additional file 1: Figure S1. Cumulative development of HCC curve
according to the etiology of LC. HCC, hepatocellar carcinoma; LC, liver
cirrhosis; HBV, hepatitis B virus; HCV, hepatitis C virus. (TIF 4549 kb)
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interval; EGD, esophagogastroduodenoscopy; HCC, hepatocellular carcinoma;
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IQR, interquartile ranges; LC, liver cirrhosis; MELD score, The Model for
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